Low-dose azacitidine, pioglitazone and all- trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase

Daniel Heudobler; Florian Luke; Joachim Hahn; Matthias Grube; Pavla Schlosser; Stephan Kremers; Thomas Sudhoff; Jorg Westermann; Marie Luise Hutter-Kronke; Richard F Schlenk; Daniela Weber; Peter Paschka; Florian Zeman; Hartmut Dohner; Wolfgang Herr; Albrecht Reichle; Simone Thomas

doi:10.3324/haematol.2023.283864

Low-dose azacitidine, pioglitazone and all- trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase

Haematologica. 2024 Apr 1;109(4):1274-1278. doi: 10.3324/haematol.2023.283864.

Authors

Daniel Heudobler¹, Florian Luke², Joachim Hahn³, Matthias Grube³, Pavla Schlosser³, Stephan Kremers⁴, Thomas Sudhoff⁵, Jorg Westermann⁶, Marie Luise Hutter-Kronke⁷, Richard F Schlenk⁸, Daniela Weber⁹, Peter Paschka⁹, Florian Zeman¹⁰, Hartmut Dohner⁹, Wolfgang Herr³, Albrecht Reichle³, Simone Thomas¹¹

Affiliations

¹ University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Bavarian Center for Cancer Research, University Hospital Regensburg, Regensburg. daniel.heudobler@ukr.de.
² University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg.
³ University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology.
⁴ Caritaskrankenhaus Lebach, Department of Hematology/Oncology.
⁵ Klinikum Passau, Department Hematology and Oncology.
⁶ Charite- University Medical Center Berlin- Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Berlin.
⁷ Charite- University Medical Center Berlin- Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Berlin, Germany; University Hospital Ulm, Department of Internal Medicine III.
⁸ National Center of Tumor Diseases Trial Center, German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany; Heidelberg University Hospital, Department of Internal Medicine V, Heidelberg.
⁹ University Hospital Ulm, Department of Internal Medicine III.
¹⁰ Center for Clinical Studies, University Hospital Regensburg, Regensburg.
¹¹ University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Leibniz Institute for Immunotherapy, Division of Genetic Immunotherapy, Regensburg.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Azacitidine* / adverse effects
Humans
Induction Chemotherapy / methods
Leukemia, Myeloid, Acute* / drug therapy
Pioglitazone / therapeutic use
Treatment Outcome
Tretinoin / adverse effects

Substances

Azacitidine
Pioglitazone
Tretinoin

Grants and funding

Funding: This work was supported by Celgene and the Anticancer Fund.